WP
DRUG

Woodline Partners’s Bright Minds Biosciences DRUG Stock Holding History

Woodline Partners’s Portfolio DRUG Stock Details DRUG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.21M Hold
45,668
– – 0.01% 780
2026
Q1 		$3.33M Buy
+45,668
New +$3.68M 0.01% 732

Other funds holding DRUG

JT
Jupiter Topco New York $245B AUM
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Woodline Partners's DRUG Position: Q2 2026 in Review

Woodline Partners held its Bright Minds Biosciences (DRUG) position steady in Q2 2026 at 45,668 shares worth $3.21M. The position accounts for 0.01% of the portfolio, ranked #780.

Woodline Partners first reported a position in DRUG in Q1 2026 and has held it in 2 quarters since. The position peaked at $3.33M in Q1 2026. 100 funds tracked by Wall St. Rank hold DRUG as of Q2 2026.

  • Woodline Partners held 45,668 shares of Bright Minds Biosciences worth $3.21M as of Q2 2026.
  • Woodline Partners left its Bright Minds Biosciences share count unchanged in Q2 2026.
  • Bright Minds Biosciences made up 0.01% of Woodline Partners's portfolio in Q2 2026, its #780 holding.
  • Woodline Partners first reported a position in Bright Minds Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Woodline Partners's Bright Minds Biosciences position peaked at $3.33M in Q1 2026.
  • 100 funds tracked by Wall St. Rank held Bright Minds Biosciences as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.